Notably, treatment with oAd/APP+DC led to significantly improved retainment of intratumorally administered exogenous DCs compared to DC alone (Figures 4B, C), suggesting that combination therapy attenuates immunosuppression-mediated inactivation and clearance of DCs from tumor tissues. The gene discussed is APP; the disease is neoplasm.